Mountain High Acquisitions Competitors

Mountain High Acquisitions (OTCMKTS:MYHI) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Profitability

This table compares Mountain High Acquisitions and Abacus Health Products' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and price targets for Mountain High Acquisitions and Abacus Health Products, as provided by MarketBeat.

Valuation and Earnings

This table compares Mountain High Acquisitions and Abacus Health Products' gross revenue, earnings per share and valuation.

Acreage (OTCMKTS:ACRGF) and Mountain High Acquisitions (OTCMKTS:MYHI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Acreage and Mountain High Acquisitions' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Acreage and Mountain High Acquisitions' top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Acreage and Mountain High Acquisitions, as provided by MarketBeat.

Acreage currently has a consensus target price of $8.4333, indicating a potential upside of 204.45%. Given Acreage's higher possible upside, equities research analysts plainly believe Acreage is more favorable than Mountain High Acquisitions.

Summary

Acreage beats Mountain High Acquisitions on 2 of the 2 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and Mountain High Acquisitions (OTCMKTS:MYHI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Profitability

This table compares Applied Biosciences and Mountain High Acquisitions' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for Applied Biosciences and Mountain High Acquisitions, as reported by MarketBeat.

Earnings and Valuation

This table compares Applied Biosciences and Mountain High Acquisitions' top-line revenue, earnings per share (EPS) and valuation.

Mountain High Acquisitions (OTCMKTS:MYHI) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Mountain High Acquisitions and Ayr Strategies, as reported by MarketBeat.

Ayr Strategies has a consensus price target of $34.8571, indicating a potential upside of 63.96%. Given Ayr Strategies' higher possible upside, analysts plainly believe Ayr Strategies is more favorable than Mountain High Acquisitions.

Earnings & Valuation

This table compares Mountain High Acquisitions and Ayr Strategies' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Mountain High Acquisitions and Ayr Strategies' net margins, return on equity and return on assets.

Summary

Ayr Strategies beats Mountain High Acquisitions on 2 of the 2 factors compared between the two stocks.

Mountain High Acquisitions (OTCMKTS:MYHI) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Mountain High Acquisitions and Can B, as reported by MarketBeat.

Earnings & Valuation

This table compares Mountain High Acquisitions and Can B's revenue, earnings per share and valuation.

Profitability

This table compares Mountain High Acquisitions and Can B's net margins, return on equity and return on assets.

Cansortium (OTCMKTS:CNTMF) and Mountain High Acquisitions (OTCMKTS:MYHI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Cansortium and Mountain High Acquisitions, as reported by MarketBeat.

Cansortium presently has a consensus price target of $1.20, suggesting a potential upside of 6.10%. Given Cansortium's higher probable upside, analysts clearly believe Cansortium is more favorable than Mountain High Acquisitions.

Earnings and Valuation

This table compares Cansortium and Mountain High Acquisitions' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Cansortium and Mountain High Acquisitions' net margins, return on equity and return on assets.

Summary

Cansortium beats Mountain High Acquisitions on 2 of the 2 factors compared between the two stocks.